Literature DB >> 10653855

Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes.

F Puppo1, P Contini, M Ghio, S Brenci, M Scudeletti, G Filaci, S Ferrone, F Indiveri.   

Abstract

In the present study, we have evaluated the apoptotic effect of soluble human MHC class I (sHLA-I) antigens on CD8(+) T lymphocytes. sHLA-I antigens and beta(2)-microglobulin-free HLA class I heavy chains, isolated from serum, induced apoptosis on phytohemagglutinin-activated CD8(+) T lymphocytes in autologous and allogeneic combinations. The extent of CD8(+) T cell apoptosis depends on the degree of activation, time of incubation with sHLA-I antigens and amount of sHLA-I antigens added to the cultures. Apoptosis is induced by the interaction of Fas (CD95)(+) cells with soluble Fas ligand which is released following binding of sHLA-I antigens to CD8 molecules. These results suggest that sHLA-I antigens may regulate immune responses by inducing apoptosis in activated CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10653855     DOI: 10.1093/intimm/12.2.195

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  18 in total

1.  Soluble plasma HLA peptidome as a potential source for cancer biomarkers.

Authors:  Michal Bassani-Sternberg; Eilon Barnea; Ilan Beer; Irit Avivi; Tami Katz; Arie Admon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

2.  sHLA-I Contamination, a novel mechanism to explain ex vivo/in vitro modulation of IL-10 synthesis and release in CD8(+) T lymphocytes and in neutrophils following intravenous immunoglobulin infusion.

Authors:  Massimo Ghio; Paola Contini; Maurizio Setti; Gianluca Ubezio; Clemente Mazzei; Gino Tripodi
Journal:  J Clin Immunol       Date:  2010-02-02       Impact factor: 8.317

3.  Effect of storage period of red blood cell suspensions on helper T-cell subpopulations.

Authors:  Salih H Bal; Yasemin Heper; Levent T Kumaş; Furkan Guvenc; Ferah Budak; Güher Göral; Haluk B Oral
Journal:  Blood Transfus       Date:  2017-03-15       Impact factor: 3.443

4.  Partial activation and induction of apoptosis in CD4(+) and CD8(+) T lymphocytes by conformationally authentic noninfectious human immunodeficiency virus type 1.

Authors:  M T Esser; J W Bess; K Suryanarayana; E Chertova; D Marti; M Carrington; L O Arthur; J D Lifson
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from healthy donors and patients produced with three different techniques.

Authors:  Gianluca Ubezio; Massimo Ghio; Paola Contini; Roberta Bertorello; Gennaro Marino; Andrea Tomasini; Gino Tripodi
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

Review 6.  Myelomagenesis: capturing early microenvironment changes.

Authors:  Neha Korde; Irina Maric
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

7.  Effect of major burns on early and late activating markers of peripheral blood T lymphocytes.

Authors:  S Sayed; R Bakry; M El-Shazly; M El-Oteify; S Terzaki; M Fekry
Journal:  Ann Burns Fire Disasters       Date:  2012-03-31

Review 8.  Soluble HLA-G: Are they clinically relevant?

Authors:  Vito Pistoia; Fabio Morandi; Xinhui Wang; Soldano Ferrone
Journal:  Semin Cancer Biol       Date:  2007-07-31       Impact factor: 15.707

9.  Blood transfusions with high levels of contaminating soluble HLA-I correlate with levels of soluble CD8 in recipients' plasma; a new control factor in soluble HLA-I-mediated transfusion-modulated immunomodulation?

Authors:  Massimo Ghio; Paola Contini; Gianluca Ubezio; Filippo Ansaldi; Maurizio Setti; Gino Tripodi
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

Review 10.  Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.

Authors:  M Campoli; S Ferrone
Journal:  Tissue Antigens       Date:  2008-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.